The New Zealand Government has announced the biggest reforms to the science sector in 30 years as part of a package to accelerate economic growth. Prime Minister Christopher Luxon said the changes aim to double exports by 2034 and maximise the value of NZ$1.2 billion annual science spending. The core change is restructuring seven Crown Research Institutes into three new public research organisations, focusing on earth sciences, bioeconomy, health and forensic science, which will seek private sector investment.

A new New Zealand Investment Agency will be established to promote foreign direct investment, and a new national intellectual property management policy is planned to allow researchers to profit from their work. The Government will also lift a 30-year ban on genetic engineering research, allowing field trials. However, scientists note the reforms do not address long-term underinvestment: New Zealand's public science spending as a share of GDP is about half that of Denmark.

As a cost-cutting measure, several Crown Research Institutes laid off hundreds of staff last year and plan to close Callaghan Innovation, which employs nearly 400 people. Many scientists are leaving New Zealand due to reduced funding for basic research. The reform plan adopts some recommendations from an advisory panel but downplays warnings not to expect huge or immediate returns.

New funding is unlikely until the 2026 budget, and the reforms may lead to more job losses in the science sector.

For small and medium enterprise (SME) owners, the reforms pose short-term uncertainty but may bring new business opportunities in the long run. On one hand, the restructuring of Crown Research Institutes and closure of Callaghan Innovation mean SMEs that rely on these bodies for R&D support or collaboration may lose access to technology incubation, commercialisation guidance and partnership channels in the near term. An exodus of scientists could weaken New Zealand's overall R&D capability, affecting technical consulting and talent recruitment.

On the other hand, lifting the genetic engineering ban opens a new window for SMEs in agriculture and biotechnology – if legislation passes, they could conduct field trials of genetically modified crops, develop high-value varieties, or boost export competitiveness. The new IP policy encourages researchers to profit from their work, allowing SMEs more flexibility to access innovative technologies through patent licensing or collaborative development. Additionally, the New Zealand Investment Agency's efforts to attract foreign capital may drive local supply chain demand, for instance by providing ancillary services to incoming international tech firms.

However, the reforms emphasise a commercialisation focus, and the weakening of basic research may undermine long-term innovation foundations. SMEs relying on public scientific knowledge should assess changes in access channels. It is advisable to monitor the 2026 budget funding allocation and the specific cooperation models of the new bodies, adjusting technology strategies accordingly.

Looking ahead, the genetic engineering lift and new investment agency could create niche opportunities for SMEs, but policy implementation details are awaited.

Keywords: New Zealand, science reform, Crown Research Institutes, genetic engineering, investment agency, intellectual property, commercialisation, research organisations, job cuts, economic growth

新西兰政府宣布30年来最大规模科学机构改革，作为加速经济增长一揽子措施的一部分。总理Christopher Luxon表示改革旨在到2034年使出口翻倍，并最大化每年12亿新西兰元科学投入的价值。核心变化是将7个皇家研究所重组为3个新公共研究机构，重点领域为地球科学、生物经济、健康和法医科学，这些新机构将寻求私营部门投资。

同时成立新西兰投资局以促进外国直接投资，并计划制定新的国家知识产权管理政策使研究人员从成果中获利。此外，政府将解除长达30年的基因工程研究禁令，允许实地试验。但科学家团体指出改革未解决长期投资不足问题：新西兰科学公共支出占GDP比例约为丹麦的一半。

作为削减成本措施，几个皇家研究机构去年已解雇数百人，并计划关闭拥有近400名员工的卡拉汉创新公司。许多科学家因基础科学投资减少而离开新西兰。改革计划采纳了咨询小组部分建议，但淡化了关于不要期待巨额或立竿见影回报的警告。

新资金在2026年预算前不太可能到位，改革可能导致科学部门更多失业。

这项改革对中小企业主而言，短期面临不确定性，但长期可能带来新的商业机会。一方面，皇家研究所重组和卡拉汉创新公司关闭，使得依赖这些机构获取研发支持或合作的中小企业，短期内可能失去技术孵化、商业化指导及合作渠道。科学家离职潮可能削弱新西兰整体研发能力，影响技术咨询和人才招聘。

另一方面，基因工程禁令解除为农业、生物技术领域的中小企业打开新窗口——若立法通过，可在田间试验转基因作物，开发高附加值品种，或提升出口竞争力。新知识产权政策鼓励研究人员从成果中获利，中小企业可更灵活地通过专利许可或合作开发获取创新技术。此外，新西兰投资局吸引外资可能带动本地供应链需求，例如为入驻的国际科技公司提供配套服务。

但需注意改革强调商业化导向，基础研究弱化可能影响长期创新根基，中小企业若依赖公开科学知识，需评估获取渠道变化。建议关注2026年预算资金分配及新机构的具体合作模式，适时调整技术战略。展望来看，基因工程解禁和新投资局或为中小企业创造细分领域机会，但需等待政策落地细节。

关键词: 新西兰, 科学改革, 皇家研究所, 基因工程, 投资局, 知识产权, 商业化, 研究机构, 裁员, 经济增长

Photo by Leeloo The First on Pexels

Source: Sohu